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Background and purpose: We previously found considerable variation in information provision on
preoperative radiotherapy (PRT) in rectal cancer. Our aims were to reach consensus among patients
and oncologists on which beneﬁts/harms of PRT should be addressed during the consultation, and to
assess congruence with daily clinical practice.
Materials and methods: A four-round Delphi-study was conducted with two expert panels: (1) 31 treated
rectal cancer patients and (2) 35 radiation oncologists. Thirty-seven possible beneﬁts/harms were shown.
Participants indicated whether addressing the beneﬁt/harm was (1) essential, (2) desired, (3) not
necessary, or (4) to be avoided. Consensus was assumed when P80% of the panel agreed. Results were
compared to 81 audio-taped consultations.
Results: The panels reached consensus that six topics should be addressed in all patients (local control,
survival, long term altered defecation pattern and faecal incontinence, perineal wound healing problems,
advice to avoid pregnancy), three in male patients (erectile dysfunction, ejaculation disorder, infertility),
and four in female patients (vaginal dryness, pain during intercourse, menopause, infertility). On average,
less than half of these topics were addressed in daily clinical practice.
Conclusions: This study showed substantial overlap between beneﬁts/harms that patients and oncolo-
gists consider important to address during the consultation, and at the same time poor congruence with
daily clinical practice.
 2014 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 114 (2015) 212–217
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/3.0/).Preoperative radiotherapy (PRT) improves local control of rectal
cancer. Although not demonstrated in randomised controlled tri-
als, there might be a small survival beneﬁt at the population level
[1,2]. Due to the good local control with surgery alone, there is a
high number needed to treat to prevent one local recurrence
[2,3]. In addition, PRT is associated with adverse outcomes, such
as higher chances of bowel and sexual dysfunction than with sur-
gery alone [3,4]. When deciding about treatment, the possible ben-
eﬁt in terms of local control should therefore be balanced against
the possible harms, taking into account patient preferences.
Patients need to be informed about the most relevant beneﬁts
and harms of treatment in order to develop a preference. Informing
patients also prevents them from overestimating the impact of
treatment on cure [5]. Moreover, patients who are well-informedexperience better health-related quality of life and may cope better
with treatment side effects [6,7].
In earlier research, we found considerable variation in informa-
tion provision regarding beneﬁts and harms of PRT during the deci-
sion consultation between rectal cancer patients and their
radiation oncologist [8]. This variation indicates a lack of clarity
on which beneﬁts and harms of PRT should be discussed with
newly-diagnosed patients. In general, treatment guidelines provide
little or no recommendation on which beneﬁts and harms to com-
municate to patients. The Dutch guidelines for the treatment of
rectal cancer for example state that clinicians need to ‘discuss
the possible beneﬁts and harms of radiotherapy with the patient’,
without further speciﬁcation [9].
The aims of this study were to (1) reach consensus among rectal
cancer patients and radiation oncologists and compose a core list
of beneﬁts and harms of PRT that should minimally be addressed
during the decision consultation, and (2) assess congruence with
daily clinical practice.
Table 1
Beneﬁts and harms of preoperative radiotherapy presented in the ﬁrst Delphi-round.
1. Local control
2. Overall survival
3. Secondary tumours
4. Altered defecation pattern (short term)
5. Altered defecation pattern (long term)
6. Faecal incontinence (short term)
7. Faecal incontinence (long term)
8. Soiling
9. Increased rectal blood loss
10. Decreased rectal blood loss
11. Small bowel adhesions
12. Bladder dysfunction
13. Urinary incontinence
14. Infertility (women)
15. Infertility (men)
16. Avoidance of pregnancy
17. Erectile dysfunction (men)
18. Ejaculation disorder (men)
19. Vaginal dryness (women)
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Participants
A Delphi study was performed in two panels: treated rectal can-
cer patients and radiation oncologists. One of the most critical
requirements in the Delphi method is the selection of experts, rich
in information and experience [10]. Eligible patients had received
radiotherapy and had ﬁnished their oncologic treatment at least
4 months ago. Patients treated at the Leiden University Medical
Center who participated in an earlier study were approached via
mail. Furthermore, members of the Dutch colorectal cancer patient
organization were approached through the monthly newsletter of
their association. Members of the Gastrointestinal-subsection of
the Dutch Society for Radiation Oncology were approached for par-
ticipation. All 45 radiation oncologists who were members of this
platform were considered to be clinical experts.
We aimed to include at least half of the radiation oncologists
from the platform, and an equal number of rectal cancer patients.20. Pain during intercourse (women)
21. Menopause (women)
22. Anastomotic leakage
23. Increased blood loss during surgery
24. Abdominal wound healing problems
25. Perineal wound healing problems
26. Increased readmission rate
27. Nerve damage (short term)
28. Nerve damage (long term)
29. Muscle weakness
30. Skin irritation
31. Hair loss (local)
32. Fatigue
33. Longer recovery
34. Feeling unwell
35. Less appetite
36. Cardiovascular problems
37. FistulaDesign
In order to reach consensus, we used the Delphi technique. This
is a structured process that uses a series of questionnaires or
‘rounds’ to gather information until consensus in the panels is
reached [11]. As we expected differences in opinions between
patients and radiation oncologists, we aimed to reach consensus
in each panel separately [12]. Based on previous Delphi studies,
we intended a maximum of three online rounds in which partici-
pants could indicate which beneﬁts and harms should always be
addressed during the decision consultation [11]. Since there was
only consensus on a limited number of beneﬁts/harms after three
rounds, we organized additional and separate consensus meetings
with a fourth and ﬁnal voting round. Between January and
September 2013, the participants completed an iterative series of
four questionnaires with feedback reports. In the ﬁrst online
questionnaire, socio-demographic and treatment- (patients) or
work- (radiation oncologists) related details were obtained.
To assess congruence between the results of this Delphi-study
and daily clinical practice, we compared the core list that was
obtained to results of a previous study on information provision
regarding beneﬁts and harms of PRT [8]. In that study, we audio-
taped and analysed 81 decision consultations between radiation
oncologists and rectal cancer patients.Questionnaire rounds
The ﬁrst questionnaire consisted of 37 beneﬁts and harms,
ordered by subject matter (see Table 1). These were obtained from
all beneﬁts/harms that had been discussed in any of the ﬁrst 45 of
81 previously audio taped decision consultations between radia-
tion oncologists and rectal cancer patients [8]. Beneﬁts/harms
related to inconvenience or costs were excluded. We comple-
mented the list with outcomes described in the literature
[2,3,13–18]. This led to a total of 30 outcomes on which PRT could
have an effect for all patients, three for male patients only, and four
for female patients only. In both panels, the same brief description
of the items was given to help minimize interpretation differences.
Information on probable prevalence was given in words and ranges
(rare: 0–5%; sometimes: 5–25%; often: 25–75%; (almost) always:
75–100%).
Participants were asked to indicate whether they thought that
addressing the outcome during the ﬁrst consultation was (1)
essential, (2) desired, (3) not necessary, or (4) to be avoided.
Participants were asked to respond to all outcomes. For example,
all participants (including female patients) were asked to indicatethe importance of addressing ‘erectile dysfunction’ during consul-
tations with male patients. After each subject matter, participants
could comment on the item descriptions or suggest additional out-
comes. The ﬁrst questionnaire was pilot-tested in eight radiation
oncologists and eight lay people. The ﬁnal version of the ﬁrst ques-
tionnaire was adjusted according to their feedback.
Based on the literature, we deﬁned consensus as at least 80% of
the participants in one panel ticking the same answer category
(e.g., 1 ‘essential’) and no more than 15% an answer category two
or three categories away (e.g., 3 ‘not necessary’ or 4 ‘avoid’) [11].
Outcomes on which consensus was reached were removed from
the subsequent questionnaire(s). The other items were included
in the subsequent questionnaire, together with feedback on the
responses of the panel and the participant’s own responses. Radia-
tion oncologists also received feedback on patients’ responses.
Feedback on participants’ responses in each of the categories was
shown as a percentage and a column bar. In the second and third
questionnaire, participants were asked to reconsider their previ-
ously given responses in light of the opinion of other panel
members.Consensus meetings
After the three online questionnaires, we organized a separate
in-person consensus meeting for each panel, with the aim to dis-
cuss the importance of addressing beneﬁts/harms for which no
consensus had been reached in the online rounds. All participants
who had completed the third round were invited. The meetings
Table 2
Participant characteristics in round 1.
N (%)
Patients (N = 31)
Member of patient association 10 (32)
Mean age, years ± s.d. (range) 64 ± 10.7 (32–85)
Mean time since diagnosis, years ± s.d. (range) 2 ± 2.2 (0.3–9)
Male 18 (58)
Educational levela
214 Delphi beneﬁts/harms of PRT to addressstarted with a brief presentation on the background of the study,
followed by the results up to then. After a group discussion on
the importance of addressing the beneﬁts and harms, participants’
ﬁnal opinions were assessed anonymously.
At the consensus meeting, several participants indicated that
the response categories 1 (essential) and 2 (desired) were only
marginally different. We therefore decided to merge these catego-
ries in the analysis of the responses in this ﬁnal round.Low 2 (7)
Intermediate 16 (55)
High 11 (38)
Neo-adjuvant treatment
PRT (5x5 Gy) 19 (61)
Chemoradiation 12 (39)
Stoma
No stoma 12 (34)
Temporary 11 (36)
Permanent 8 (26)
Radiation oncologists (N = 35)
Mean age, years ± s.d. (range) 47 ± 8.1 (35–66)
Mean time since specialization, years ± s.d. (range) 12 ± 9.0 (2–39)
Mean number of new rectal cancer patients per 5 ± 2.3 (1–10)Statistical analyses
Responses of patients and radiation oncologists were analysed
separately. Descriptive statistics were used to report patients’
and radiation oncologists’ characteristics, their views on which
beneﬁts and harms should be addressed and congruence between
the results of this study and daily clinical practice. Using Chi-
square tests and Mann–Whitney U tests, characteristics and
responses of participants who did versus did not complete the
study were compared. A two-sided p-value of 60.05 was consid-
ered statistically signiﬁcant.month ± s.d. (range)
Male 12 (34)
Current institution
Academic teaching centre 14 (40)
Non-academic teaching centre 12 (34)
Non-teaching centre 9 (26)
a Educational levels included low = completed no/primary school, intermedi-
ate = completed lower general secondary education/vocational training; or
high = completed pre-university education/high vocational training/university. Two
patients did not respond to this question.Results
Of the 38 eligible patients approached, 23 (61%) completed the
ﬁrst questionnaire. An additional eight were included through the
patient organization. Of these 31 patients, 28 patients completed
the second and third questionnaires (90% of those who started).
Ten patients attended the consensus meeting and completed the
ﬁnal voting round (36% of those who completed the third
questionnaire).
Of the 45 radiation oncologists who are members of the plat-
form, 35 (78%) completed the ﬁrst questionnaire. The second and
third questionnaires were completed by 32 and 29 oncologists,
respectively (91% and 83% of started, 71% and 64% of total). All
29 oncologists who completed the third round also completed
the ﬁnal voting round.
In Table 2 participant demographic and treatment- (patients) or
work- (oncologists) related characteristics are listed. Radiation
oncologists working at a non-teaching centre compared to an aca-
demic or non-academic teaching centre signiﬁcantly more often
declined further participation in the study (N = 4, 44% vs. N = 1,
8% vs. N = 1, 7%; v2 = 6.36, p < 0.05). Otherwise, no signiﬁcant dif-
ferences were found between characteristics of participants who
did versus did not complete the study. To assess bias caused by
the 36% response rate of the consensus meeting, we compared
the scores in round 3 of attenders and non-attenders. We found
that patients who attended the consensus meeting rated ‘bladder
dysfunction’ as signiﬁcantly more important than patients who
did not attend the consensus meeting (v2 = 10.04, p < 0.01). After
receiving feedback on the answers given in round 3 and a discus-
sion during the consensus meeting, patients eventually reached
consensus that this outcome need not necessarily be discussed.
Otherwise, no signiﬁcant differences were found between the
answers of those who did versus those who did not attend the con-
sensus meeting.
Patients and radiation oncologists reached consensus on,
respectively, 29 and 30 of the 37 beneﬁts/harms. Both panels
agreed that six beneﬁts/harms should be addressed with all
newly-diagnosed rectal cancer patients, together with three bene-
ﬁts/harms for male patients only and four for female patients only.
They also agreed that 11 beneﬁts/harms need not necessarily be
addressed. According to the panels, none of the beneﬁts/harms
should be avoided during the ﬁrst consultation. The ﬁnal core list
of beneﬁts/harms that should be addressed and items that need
not necessarily be addressed can be found in Table 3.In total, there were 11 topics on which one panel reached
consensus, and the other panel did not. On two topics, patients’
and oncologists’ opinions were almost contrary. Patients agreed
that ‘increased readmission rate’ should be addressed, while oncol-
ogists approached consensus that this is not necessary (72% agree-
ment). Also, oncologists agreed that ‘short-term altered defecation
pattern’ should be addressed, while patients tended to rate this as
‘not necessary’ (60% agreement).
To assess congruence between the results from the Delphi-
study and daily clinical practice, we compared the core list to
results on information provision regarding beneﬁts and harms of
PRT, based on 81 audiotaped decision consultations [8]. We found
that in daily clinical practice, male patients received information
on 3.3 (37%) of the nine topics from the core list (range, 1–6) on
average. Female patients on average received information on 3.2
(32–46%) of the seven topics from the core list for postmenopausal
women or 10 topics for premenopausal women (range, 1–6). In
none of the 81 audiotaped consultations, all beneﬁts/harms as
deﬁned in the core list were addressed. As can be seen in Fig. 1,
only the effect of PRT on local control was addressed in all consul-
tations. There were seven (9%) consultations in which local control
was the only topic from the core list that was addressed.
Several topics which are not on the core list are frequently
addressed in consultations. Both panels reached consensus that
‘skin problems’ and ‘feeling unwell’ are not necessary to address
in the ﬁrst consultation. In daily clinical practice, these topics were
addressed in 27% and 31% of the consultations, respectively. In
addition, the patient panel agreed that ‘fatigue’ and ‘bladder dys-
function’ need not necessarily be addressed. In respectively 53
and 70% of consultations, patients received information on these
harms of treatment.
Discussion
The ﬁrst aim of this study was to reach consensus among rectal
cancer patients and radiation oncologists on which beneﬁts and
Table 3
Beneﬁts and harms of PRT that should be or need not be addressed with newly-diagnosed rectal cancer patients, and number of rounds needed by expert panel before reaching consensus.
a Men and premenopausal women only.
b Premenopausal women only.
Note: Light grey shades refer to beneﬁts/side effects concerning male patients only, dark grey shades refer to beneﬁts/side effects concerning female patients only.
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Fig. 1. Topics which should be addressed and the percentage of consultations in which the beneﬁt/harm was addressed. Note: * as a percentage of consultations with patients
from relevant patient group (male/female patients).  Only relevant for patients undergoing abdominoperineal resection, all patients in our sample underwent a low anterior
resection. ST = on the short term; LT = on the long term. Black bars = consensus in both panels, Grey bars = consensus in radiation oncologist panel only.
216 Delphi beneﬁts/harms of PRT to addressharms of PRT should minimally be addressed in the decision con-
sultation. The patient and oncologist panels agreed that six bene-
ﬁts/harms should be addressed with all newly-diagnosed rectal
cancer patients, together with three beneﬁts/harms for male
patients only and four for female patients only. It is noteworthy
that all topics in the ﬁnal core list are long-term beneﬁts/harms.
Indeed, during the consensus meeting, patients indicated to be less
interested in temporary short-term effects. The long-term beneﬁts/
harms include the effect of PRT on local control, survival, defeca-
tion and sexual functioning, and these effects are well-established
and described in the literature [1–3].
Of particular interest are the topics on which panels had differ-
ent opinions. Firstly, oncologists reached consensus that ‘short-
term altered defecation pattern’ should be addressed during the
consultation, but patients’ opinion differed. This might be due to
the fact that most patients already experience an altered defeca-
tion pattern at the time of the consultation. Secondly, oncologists
agreed that ‘short-term nerve damage’ should be addressed, while
patients’ opinions were divided. Because of the very low preva-
lence of short term nerve damage and patients’ bias towards their
own experiences, it might be difﬁcult for patients to understand
the consequences of this harm, despite the description we pro-
vided. This lack of consensus highlights that oncologists should
be aware that patients’ information needs might differ from what
they themselves consider important to address.
The second aim of the study was to assess congruence between
the core list and daily clinical practice. We found that patients
received information on a limited number of topics from the core
list. On average, less than half of the topics from the list were
addressed during the consultation. Even more importantly, almost
one in ten patients received no information on any of the adverse
effects that should have been addressed, according to both patients
and radiation oncologists. The need for implementing this list in
daily clinical practice is therefore clearly demonstrated.
Panels agreed that several topics not necessarily need to be
addressed with newly-diagnosed patients. Some of these topics
are nevertheless discussed in a large part of the audiotaped consul-
tations. Possible reasons to address these topics may have to do
with patient characteristics or patient’s question asking behavior.
In previous research we found that four out of ﬁve patients didnot initiate discussion on any beneﬁts/harms by asking questions
or raising new topics. Furthermore, no clear association between
beneﬁts/harms mentioned and patient’s characteristics such as
gender, age or educational level was seen. However, factors like
co-morbidity and medical history of individual patients might give
a reason to discuss certain additional topics.
Our study has some limitations. Firstly, although we pilot-
tested our questionnaire and panellists were given the opportunity
to comment on the questionnaire in each round, participants only
indicated during the consensus meeting that the meaning of the
answer categories ‘essential’ and ‘desired’ was only marginally dif-
ferent. We decided to merge these categories in the analysis of the
responses on the ﬁnal round. Had we started the Delphi study with
three categories, consensus on some topics might have been
reached earlier. Secondly, of the 28 patients who completed the
third questionnaire, only 10 patients attended the consensus meet-
ing and completed the ﬁnal questionnaire. However, the character-
istics of patients who attended compared to those who declined
further participation did not differ signiﬁcantly. Although there
was a signiﬁcant difference in how attending and non-attending
patients valued the discussion of ‘Bladder irritation’, the attenders
converged to the opinion of the larger group of non-attenders on
this topic. Finally, we have no information on which adverse effects
of PRT the members of our patient panel experienced during or
after their treatment. Therefore, we cannot make any statements
on the inﬂuence of patients’ own experience on their views about
whether or not to address the beneﬁts/harms offered in our
questionnaire.
Delphi-methods have been used before in order to develop core
lists. However, so far no studies have been published on core lists
of beneﬁts and harms of treatment to be communicated to patients
during the consultation. Even though previous research has shown
that cancer patients have a strong need for information about side
effects of treatment [19,20], our study showed that treated
patients are capable of prioritizing those beneﬁts/harms they think
are necessary to address during the consultation. Therefore,
patients’ perspectives are valuable when creating core lists. The
method we used thus seems feasible for creating core lists for other
treatments and other cancer types. As can be seen from a number
of recent publications, the interest in the sequelae of rectal cancer
M. Kunneman et al. / Radiotherapy and Oncology 114 (2015) 212–217 217treatment, and other cancer treatments as well, is rising [21,22].
Our study is thus timely in showing a feasible method to determine
which such sequelae should be communicated with patients dur-
ing the consultation.
In conclusion, our results showed substantial overlap between
which beneﬁts and side effects of PRT patients and radiation oncol-
ogists consider important to address in the ﬁrst consultation. These
topics were poorly addressed in daily clinical practice. Our core list
can be supplemented with outcomes of relevance to the individual
patient. Addressing information on these major outcomes of PRT
will better enable individual rectal cancer patients to balance pos-
sible side effects against the possible beneﬁt in local control when
deciding about PRT.
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